In the CD73-high population, OS benefit was observed in the CD8-high population, PDL1 tumor cell–negative population, and patients with low tumor mutational burden (TMB), KRAS mutations, or without homologous recombination repair mutations when comparing arm A3 with arm A1 (Supplementary Fig. S2B). Here, KRAS is linked to neoplasm.